Delcath Systems Presents Data Regarding Its Clinical Development Programs At European Society For Medical Oncology Congress 2026; Presents Publication Of Analysis Of Percutaneous Hepatic Perfusion With Melphalan Using CHEMOSAT Hepatic Delivery Systems

Benzinga · 1d ago

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced presentations related to its clinical development programs at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid, Spain. The Company also highlighted the publication of an independent, investigator-led analysis of percutaneous hepatic perfusion (PHP) with melphalan using the CHEMOSAT® Hepatic Delivery System in patients with liver-dominant metastatic uveal melanoma (mUM).